Between 2021 and 2023, prescriptions for semaglutide-based medications increased by more than 300%, with a significant portion issued to non-diabetic patients (IQVIA Institute, 2024)
Generic versions remain 5 to 7+ years away, but manufacturer competition and government pressure are driving prices lower faster than the patent timeline alone would suggest
This cutting-edge technology offers a detailed view of your bodys composition, empowering you with the insights needed for long-term success
In March of this year, Wegovy was approved for overweight or obese patients with cardiovascular disease
Cagrilintide's ~160-hour half-life means it accumulates with repeated dosing, so the 3x/week schedule is described as providing sustained receptor activation
Immune System Support Injectable glutathione bolsters the immune system, aiding in disease and infection resistance